您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (1): 36-40.doi: 10.6040/j.issn.1671-7554.0.2018.1316

• • 上一篇    

PSMA SPECT/CT检查引导下的挽救性淋巴结清扫术在生化复发前列腺癌患者治疗中的价值

宿恒川1,朱耀1,戴波1,刘畅2,胡四龙2,叶定伟1   

  1. 1.复旦大学附属肿瘤医院泌尿外科, 复旦大学上海医学院肿瘤学系, 上海 200032;2.复旦大学附属肿瘤医院核医学科, 上海 200032
  • 发布日期:2022-09-27
  • 通讯作者: 叶定伟. E-mail:dwyeli@163.com
  • 基金资助:
    国家自然科学基金(81602222);第五批上海市青年医师培养计划(2017年)

Significance of 99mTc-PSMA SPECT/CT guided salvage lymph node dissection for prostate cancer patients with biochemical recurrence

SU Hengchuan1, ZHU Yao1, DAI Bo1, LIU Chang2, HU Silong2, YE Dingwei1   

  1. 1. Department of Urology, Shanghai Cancer Center of Fudan University, Shanghai Medical College, Fudan University, Shanghai 200032, China;
    2. Department of Nuclear Medicine, Shanghai Cancer Center of Fudan University, Shanghai 200032, China
  • Published:2022-09-27

PDF (PC)

5

摘要： 目的 探讨提高挽救性淋巴结清扫术对于生化复发前列腺癌患者的治疗效果。 方法 2015~2017年我院收治并接受前列腺特异性膜抗原(PSMA)单光子发射计算机化断层显像(SPECT)/CT检查引导下行挽救性淋巴结清扫术的前列腺癌患者,对其中3例典型患者进行回顾性分析。 结果 病例1行前列腺癌根治术(RP)后,前列腺特异性抗原(PSA)再次升高,PSMA SPECT/CT示左侧髂总血管旁肿大淋巴结,遂行双侧扩大盆腔淋巴结清扫术,术后患者PSA下降至0.2 ng/mL以下,维持8个月后再次升高;病例2 RP患者术后PSA再次升高为22 ng/mL,PSMA SPECT/CT示腹膜后淋巴结肿大,遂行腹膜后淋巴结清扫术,术后PSA逐渐下降,3个月后最低至10 ng/mL,随后再次反弹;病例3行前列腺癌根治性放疗,患者PSA下降后逐渐升至4 ng/mL,PSMA SPECT/CT示右侧髂血管旁放射性摄取增高灶,遂行扩大盆腔淋巴结清扫术+放疗,PSA下降至0.2 ng/mL以下,维持14个月后逐渐升高。 结论 对于生化复发前列腺癌患者,若PSA水平较低且出现孤立淋巴结转移灶,PSMA SPECT/CT引导下的挽救性淋巴结切除术可作为综合治疗手段之一使患者获益。

关键词: 前列腺特异性膜抗原, 前列腺癌, 转移灶, 挽救性淋巴结清扫术

Abstract: Objective To improve the value of salvage lymph node dissection for patients treated with radical prostatectomy(RP)with biochemical recurrence. Methods The clinical data of 3 typical cases treated with 99mTc-prostate-specific membrane antigen(PSMA)single photon emission computed tomography(SPECT)/CT guided salvage lymph node dissection during 2015 and 2017 were retrospectively analyzed. Results In case 1, the prostate specific antigen(PSA)control was not satisfactory after RP. PSMA SPECT/CT showed suspicious lymph node metastases near the left iliac blood vessels. After extended pelvic lymphadenectomy, the PSA level decreased to 0.2 ng/mL for 8 months and then increased again. In case 2, the PSA level increased to 22 ng/mL after RP. PSMA SPECT/CT showed suspicious retroperitoneal lymph node metastases. After retroperitoneal salvage lymph node dissection, the PSA level decreased to 10 ng/mL in 3 months and then bounced back. In case 3, after radical radiation, the PSA level gradually decreased and 山 东 大 学 学 报 (医 学 版)57卷1期 -宿恒川,等.PSMA SPECT/CT检查引导下的挽救性淋巴结清扫术在生化复发前列腺癌患者治疗中的价值 \=-then increased to 4 ng/mL. PSMA SPECT/CT showed suspicious lymph node metastases near the right iliac blood vessels. After salvage pelvic lymph node dissection plus radiation, the PSA level decreased to less than 0.2 ng/mL for 14 months and then increased. Conclusion For prostate cancer patients with biochemical recurrence, low PSA level and isolated nodal recurrence after RP, PSMA SPECT/CT guided salvage lymph node dissection can alleviate tumor burden and benefit the patients.

Key words: Prostate-specific membrane antigen, Prostate cancer, Metastatic lesions, Salvage lymph node dissection

中图分类号: 

  • R737.25
[1] Zhu Y, Wang HK, Qu YY, et al. Prostate cancer in East Asia: evolving trend over the last decade[J]. Asian J Androl, 2015, 17(1): 48-57.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[3] Pagliarulo V. Androgen deprivation therapy for prostate cancer[J]. Adv Exp Med Biol, 2018, 1096: 1-30. doi:10.1007/978-3-319-99286-0_1.
[4] Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations[J]. Prostate Cancer Prostatic Dis, 2018. doi: 10.1038/s41391-018-0079-0.
[5] Maurer T, Robu S, Schottelius M, et al. 99mTechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer[J]. Eur Urol, 2018. pii: S0302-2838(18)30189-1. doi: 10.1016/j.eururo.2018.03.013.
[6] Ploussard G, Gandaglia G, Borgmann H, et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review[J]. Eur Urol, 2018. pii: S0302-2838(18)30836-4. doi: 10.1016/j.eururo.2018.10.041.
[7] Rauscher I, Horn T, Eiber M, et al. Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands[J]. World J Urol, 2018, 36(4): 603-608.
[8] Bandini M, Fossati N, Briganti A. Salvage surgery for nodal recurrent prostate cancer[J]. Curr Opin Urol, 2017, 27(6): 604-611.
[9] Siriwardana A, Thompson J, van Leeuwen PJ, et al. Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited[J]. BJU Int, 2017, 120(5): 673-681.
[10] Montorsi F, Gandaglia G, Fossati N, et al. Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer[J]. Eur Urol, 2017, 72(3): 432-438.
[11] Rigatti P, Suardi N, Briganti A, et al. Pelvic/Retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by[11C] Choline Positron Emission Tomography/Computed Tomography[J]. Eur Urol, 2011, 60(5): 935-943.
[12] Osmonov DK, Aksenov AV, Trick D, et al. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection[J]. BMC Urol, 2016, 16(1): 56. doi:10.1186/s12894-016-0173-3.
[13] Tilki D, Mandel P, Seeliger F, et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy[J]. J Urol, 2015, 193(2): 484-490.
[14] Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years[J]. Eur Urol, 2015, 67(2): 299-309.
[15] Herlemann A, Kretschmer A, Buchner A, et al. Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/ CT for nodal recurrence in prostate cancer patients[J]. Oncotarget, 2017, 8(48): 84180-84192.
[16] Passoni NM, Suardi N, Abdollah F, et al. Utility of[11C] choline PET/CT in guiding lesion targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series[J]. Urol Oncol, 2014, 32(1): 38. e9-16. doi:10.1016/j.urolonc.2013.03.006.
[17] Oderda M, Joniau S, Palazzetti A, et al. Is 11C-choline positron emission tomography/ computed tomography accurate to detect nodal relapses of prostate cancer after biochemical recurrence? a multicentric study based on pathologic confirmation from salvage lymphadenectomy[J]. Eur Urol Focus, 2018, 4(2): 288-293.
[18] Goldstein J, Even-Sapir E, Ben-Haim S, et al. Does choline PET/CT change the management of prostate cancer patients with biochemical failure?[J]. Am J Clin Oncol, 2017, 40(3): 256-259.
[19] Leiblich A, Stevens D, Sooriakumaran P. The utility of molecular imaging in prostate cancer[J]. Curr Urol Rep, 2016, 17(3): 26. doi: 10.1007/s11934-015-0573-z.
[20] Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA positron emission tomography/ computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer[J]. Eur Urol, 2016, 70(4): 553-557.
[21] Rai BP, Baum RP, Patel A, et al. The role of positron emission tomography with(68)gallium(Ga)-labeled prostate-specific membrane antigen(PSMA)in the management of patients with organ-confined and locally advanced prostate cancer prior to radical treatment and after radical prostatectomy[J]. Urology, 2016, 95:11-15. doi:10.1016/j.urology.2015.12.048.
[22] Su HC, Zhu Y, Ling GW, et al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse[J]. Asian J Androl, 2017, 19(3): 267-271.
[23] Su HC, Zhu Y, Hu SL, et al. The value of 99mTc-PSMA SPECT/CT-guided surgery for identifying and locating lymph node metastasis in prostate cancer patients[J]. Ann Surg Oncol, 2018. doi: 10.1245/s10434-018-6805-y.
[24] Rauscher I, Düwel C, Wirtz M, et al. Value of 111 In-prostate-specific membrane antigen(PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up[J]. BJU Int, 2017, 120(1): 40-47.
[1] 许振,刁统祥,臧振杰,邵丁昌,张奇,孙鼎琪,傅强. 前列腺特异性抗原同源异构体2及其衍生指标在前列腺癌诊断中的价值[J]. 山东大学学报 (医学版), 2022, 60(6): 51-56.
[2] 孙浩瑜,姜鑫,陈守臻,曲思凤,史本康. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(6): 46-50.
[3] 史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[4] 徐兵,李勇,刘明,刘永辉. 沉默PRRX1基因表达可增强前列腺癌耐药细胞株PC-3/DTX对多西他赛的敏感性[J]. 山东大学学报 (医学版), 2021, 59(6): 103-110.
[5] 孙鼎琪,傅强,张辉,刘帅,刁统祥,曹庆伟,张克勤. 多参数磁共振与经直肠超声融合前列腺靶向穿刺活检在检测PI-RADS≥3前列腺癌中的临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 108-113.
[6] 吕家驹,胡佳林,丁森泰. 前列腺癌局部治疗的研究进展[J]. 山东大学学报 (医学版), 2019, 57(1): 1-5.
[7] 周芳坚,黄华,李永红. 前列腺癌的局灶冷冻治疗[J]. 山东大学学报 (医学版), 2019, 57(1): 6-10.
[8] 朱刚,张凯. 中国前列腺癌筛查的现状和挑战[J]. 山东大学学报 (医学版), 2019, 57(1): 11-15.
[9] 韩邦旻,荆翌峰. 寡转移前列腺癌的临床处理策略[J]. 山东大学学报 (医学版), 2019, 57(1): 26-29.
[10] 姚旭东. 局部晚期前列腺癌手术治疗策略及疗效[J]. 山东大学学报 (医学版), 2019, 57(1): 21-25.
[11] 王海涛. 去势抵抗性前列腺癌精准治疗的研究进展[J]. 山东大学学报 (医学版), 2019, 57(1): 30-35.
[12] 高振文,杨淑萍,谢雪雪,宋伟. Yes相关蛋白与结肠癌病理因素的相关性[J]. 山东大学学报 (医学版), 2018, 56(7): 57-64.
[13] 翟红运, 张登禄, 王光杰, 孔峰, 程广辉, 赵升田. 小鼠胚胎干细胞分泌因子对前列腺癌细胞作用的体外研究[J]. 山东大学学报（医学版）, 2015, 53(9): 8-12.
[14] 丁焕1，孙颖1，黎晓晴2，黎莉1. PARP抑制剂联合吉西他滨或多西他赛对雄激素非依赖性前列腺癌PC3细胞增殖的影响[J]. 山东大学学报（医学版）, 2014, 52(1): 33-36.
[15] 高逢彬，司曼飞，刘永青，牛蕾蕾，苑辉卿. 网脊衣酸上调p21CIP1蛋白诱导前列腺癌细胞周期阻滞的作用分析[J]. 山东大学学报(医学版), 2013, 51(12): 34-40.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发